POC Pharma is a technology company.
POC Pharma has raised $15.0M across 2 funding rounds.
POC Pharma has raised $15.0M in total across 2 funding rounds.
# POC Pharma: Digital Go-to-Market Solutions for Emerging Markets Pharma
POC Pharma is a SaaS company that digitizes pharmaceutical distribution and engagement in emerging markets.[1] The company provides digital go-to-market solutions designed to help pharmaceutical manufacturers, distributors, wholesalers, and pharmacies optimize their interactions and streamline operations across the retail pharmacy channel.[1][4]
The core problem POC Pharma addresses is structural inefficiency in how pharmaceutical companies reach pharmacies in emerging markets. Traditionally, pharma companies spend approximately 30% of revenues on go-to-market activities to reach only a small fraction of the 3 million pharmacies in these regions.[1] POC Pharma's platform tackles this by structuring data, connecting stakeholders along the value chain, and enabling integrated, digitalized processes that combine face-to-face and digital interactions—a model 74% of healthcare providers in Vietnam expect but rarely receive.[1]
The company has demonstrated measurable impact: teams using POC Pharma solutions have increased their market share by 24%.[1] With a dozen global and regional pharmaceutical clients already onboarded in Southeast Asia, POC Pharma is expanding into South Asia, Africa, and the Middle East.[1]
POC Pharma was founded in 2019 by Thomas Miklavec, who serves as founder and CEO.[1] The company emerged from a clear observation: the traditional pharmaceutical go-to-market model was fundamentally broken, particularly in emerging markets where population growth and healthcare demand are highest, yet distribution infrastructure remains fragmented.[1]
The founding team brought extensive experience in pharma, data, and technology across emerging markets, positioning them to understand both the pain points of pharmaceutical companies and the operational realities of retail pharmacy networks.[6] Rather than starting in mature markets, the founders chose to build in regions where the problem was most acute and where digitalization could deliver outsized impact.
POC Pharma sits at the intersection of two powerful trends: healthcare digitalization in emerging markets and B2B marketplace efficiency.[1]
Emerging markets are experiencing faster digitalization adoption than mature economies, yet pharmaceutical distribution remains one of the least digitized segments of healthcare.[1] This creates a unique opportunity: while Western pharma companies have invested heavily in CRM and analytics infrastructure, their counterparts in Asia, Africa, and the Middle East operate with fragmented, manual processes. POC Pharma's timing is advantageous because it arrives as these markets simultaneously experience rising healthcare demand, growing pharmaceutical consumption, and increasing pressure to improve access to treatment.
The company also reflects a broader shift in B2B software toward vertical SaaS solutions—specialized platforms that solve deep problems within specific industries rather than offering horizontal tools. By focusing exclusively on the pharmacy channel and the stakeholders within it, POC Pharma can optimize for the unique workflows, data structures, and regulatory requirements of pharmaceutical distribution in ways generic platforms cannot.
POC Pharma is well-positioned to become a critical infrastructure layer for pharmaceutical distribution in emerging markets. As healthcare spending accelerates in Asia, Africa, and the Middle East, and as regulatory bodies increasingly demand transparency and data integrity in drug distribution, demand for digitalized solutions will intensify.
The company's expansion strategy—opening hubs in new regions and onboarding clients across geographies—suggests confidence in a repeatable model. The key question ahead is whether POC Pharma can maintain its focus on the pharmacy channel while scaling internationally, or whether it will need to expand vertically into adjacent healthcare segments (hospitals, clinics, treatment centers) to sustain growth.
What makes POC Pharma compelling is not just the software, but the recognition that emerging market pharma distribution is a solvable problem—one where modest efficiency gains translate into massive improvements in healthcare access and company profitability. In a landscape where healthcare infrastructure in developing regions remains a critical global challenge, POC Pharma's approach of digitizing the last-mile distribution network addresses a need that will only grow more urgent.
POC Pharma has raised $15.0M in total across 2 funding rounds.
POC Pharma's investors include Alven, Bain Capital Ventures, Bond, Daffy, DNX Ventures, FJ Labs, Flucas Ventures, Geek Ventures, Global Founders Capital, Gutter Capital, Index Ventures, Insight Partners.
POC Pharma has raised $15.0M across 2 funding rounds. Most recently, it raised $10.0M Series A in April 2022.